{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "R",
                    "alt": "C",
                    "position": "1441"
                },
                "variant_string_id": "LRRK2 R1441C"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Autosomal dominant missense mutations within the gene encoding for the LRRK2 predispose humans to develop PD (Parkinson's disease). LRRK2 is a large enzyme with multiple domains. Patients with LRRK2 mutations generally develop PD with clinical symptoms indistinguishable from idiopathic PD at around 60 - 70 years of age.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations are associated with Parkinson's disease, defining the disease mechanism relevant to the functional assay for this variant."
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study used various assays such as immunoprecipitation, kinase assays, and fluorescence microscopy to study the interaction of LRRK2 with 14 - 3 - 3 and the effects of mutations on this interaction and cellular localization. These assays are relevant to understanding the molecular basis of PD as LRRK2 - 14 - 3 - 3 interaction may be linked to PD.",
                    "judgment": "Yes",
                    "reasoning": "The general classes of assays effectively model the disease pathogenesis as they are used to investigate the role of LRRK2 mutations in PD through studying its interactions and localization.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "For the experiments, multiple replicates were not explicitly stated. However, the assays like immunoprecipitation, kinase assays, etc., are standard techniques in the field.",
                    "sub_step": "3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "judgment": "Yes",
                    "reasoning": "The specific instances of the assays are broadly accepted historically as they are standard techniques in the field.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for LRRK2 R1441C is of supporting strength as the disease mechanism is defined, the assay classes are applicable, and although basic controls and replicates were not fully met, the assays are broadly accepted in the field."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "R",
                    "alt": "G",
                    "position": "1441"
                },
                "variant_string_id": "LRRK2 R1441G"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Autosomal dominant missense mutations within the gene encoding for the LRRK2 predispose humans to develop PD (Parkinson's disease). LRRK2 is a large enzyme with multiple domains. Patients with LRRK2 mutations generally develop PD with clinical symptoms indistinguishable from idiopathic PD at around 60 - 70 years of age.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations are associated with Parkinson's disease, defining the disease mechanism relevant to the functional assay for this variant."
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study used various assays such as immunoprecipitation, kinase assays, and fluorescence microscopy to study the interaction of LRRK2 with 14 - 3 - 3 and the effects of mutations on this interaction and cellular localization. These assays are relevant to understanding the molecular basis of PD as LRRK2 - 14 - 3 - 3 interaction may be linked to PD.",
                    "judgment": "Yes",
                    "reasoning": "The general classes of assays effectively model the disease pathogenesis as they are used to investigate the role of LRRK2 mutations in PD through studying its interactions and localization.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "For the experiments, multiple replicates were not explicitly stated. However, the assays like immunoprecipitation, kinase assays, etc., are standard techniques in the field.",
                    "sub_step": "3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "judgment": "Yes",
                    "reasoning": "The specific instances of the assays are broadly accepted historically as they are standard techniques in the field.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for LRRK2 R1441G is of supporting strength as the disease mechanism is defined, the assay classes are applicable, and although basic controls and replicates were not fully met, the assays are broadly accepted in the field."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "R",
                    "alt": "H",
                    "position": "1441"
                },
                "variant_string_id": "LRRK2 R1441H"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Autosomal dominant missense mutations within the gene encoding for the LRRK2 predispose humans to develop PD (Parkinson's disease). LRRK2 is a large enzyme with multiple domains. Patients with LRRK2 mutations generally develop PD with clinical symptoms indistinguishable from idiopathic PD at around 60 - 70 years of age.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations are associated with Parkinson's disease, defining the disease mechanism relevant to the functional assay for this variant."
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study used various assays such as immunoprecipitation, kinase assays, and fluorescence microscopy to study the interaction of LRRK2 with 14 - 3 - 3 and the effects of mutations on this interaction and cellular localization. These assays are relevant to understanding the molecular basis of PD as LRRK2 - 14 - 3 - 3 interaction may be linked to PD.",
                    "judgment": "Yes",
                    "reasoning": "The general classes of assays effectively model the disease pathogenesis as they are used to investigate the role of LRRK2 mutations in PD through studying its interactions and localization.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "For the experiments, multiple replicates were not explicitly stated. However, the assays like immunoprecipitation, kinase assays, etc., are standard techniques in the field.",
                    "sub_step": "3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "judgment": "Yes",
                    "reasoning": "The specific instances of the assays are broadly accepted historically as they are standard techniques in the field.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for LRRK2 R1441H is of supporting strength as the disease mechanism is defined, the assay classes are applicable, and although basic controls and replicates were not fully met, the assays are broadly accepted in the field."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "Y",
                    "alt": "C",
                    "position": "1699"
                },
                "variant_string_id": "LRRK2 Y1699C"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Autosomal dominant missense mutations within the gene encoding for the LRRK2 predispose humans to develop PD (Parkinson's disease). LRRK2 is a large enzyme with multiple domains. Patients with LRRK2 mutations generally develop PD with clinical symptoms indistinguishable from idiopathic PD at around 60 - 70 years of age.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations are associated with Parkinson's disease, defining the disease mechanism relevant to the functional assay for this variant."
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study used various assays such as immunoprecipitation, kinase assays, and fluorescence microscopy to study the interaction of LRRK2 with 14 - 3 - 3 and the effects of mutations on this interaction and cellular localization. These assays are relevant to understanding the molecular basis of PD as LRRK2 - 14 - 3 - 3 interaction may be linked to PD.",
                    "judgment": "Yes",
                    "reasoning": "The general classes of assays effectively model the disease pathogenesis as they are used to investigate the role of LRRK2 mutations in PD through studying its interactions and localization.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "For the experiments, multiple replicates were not explicitly stated. However, the assays like immunoprecipitation, kinase assays, etc., are standard techniques in the field.",
                    "sub_step": "3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "judgment": "Yes",
                    "reasoning": "The specific instances of the assays are broadly accepted historically as they are standard techniques in the field.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for LRRK2 Y1699C is of supporting strength as the disease mechanism is defined, the assay classes are applicable, and although basic controls and replicates were not fully met, the assays are broadly accepted in the field."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "I",
                    "alt": "T",
                    "position": "2020"
                },
                "variant_string_id": "LRRK2 I2020T"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Autosomal dominant missense mutations within the gene encoding for the LRRK2 predispose humans to develop PD (Parkinson's disease). LRRK2 is a large enzyme with multiple domains. Patients with LRRK2 mutations generally develop PD with clinical symptoms indistinguishable from idiopathic PD at around 60 - 70 years of age.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations are associated with Parkinson's disease, defining the disease mechanism relevant to the functional assay for this variant."
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study used various assays such as immunoprecipitation, kinase assays, and fluorescence microscopy to study the interaction of LRRK2 with 14 - 3 - 3 and the effects of mutations on this interaction and cellular localization. These assays are relevant to understanding the molecular basis of PD as LRRK2 - 14 - 3 - 3 interaction may be linked to PD.",
                    "judgment": "Yes",
                    "reasoning": "The general classes of assays effectively model the disease pathogenesis as they are used to investigate the role of LRRK2 mutations in PD through studying its interactions and localization.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "For the experiments, multiple replicates were not explicitly stated. However, the assays like immunoprecipitation, kinase assays, etc., are standard techniques in the field.",
                    "sub_step": "3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "judgment": "Yes",
                    "reasoning": "The specific instances of the assays are broadly accepted historically as they are standard techniques in the field.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for LRRK2 I2020T is of supporting strength as the disease mechanism is defined, the assay classes are applicable, and although basic controls and replicates were not fully met, the assays are broadly accepted in the field."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "R",
                    "alt": "H",
                    "position": "1728"
                },
                "variant_string_id": "LRRK2 R1728H"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Autosomal dominant missense mutations within the gene encoding for the LRRK2 predispose humans to develop PD (Parkinson's disease). LRRK2 is a large enzyme with multiple domains. Patients with LRRK2 mutations generally develop PD with clinical symptoms indistinguishable from idiopathic PD at around 60 - 70 years of age.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations are associated with Parkinson's disease, defining the disease mechanism relevant to the functional assay for this variant."
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study used kinase assays to measure the protein kinase activity of the mutant. This is relevant to understanding the role of LRRK2 in PD as increased kinase activity may contribute to the disease mechanism.",
                    "judgment": "Yes",
                    "reasoning": "The kinase assay effectively models the disease pathogenesis by measuring a key aspect of LRRK2 function that may be affected in PD.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "For the experiments, multiple replicates were not explicitly stated. However, kinase assays are standard techniques in the field.",
                    "sub_step": "3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "judgment": "Yes",
                    "reasoning": "The kinase assay is a broadly accepted technique in the field.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for LRRK2 R1728H is of supporting strength as the disease mechanism is defined, the assay class is applicable, and although basic controls and replicates were not fully met, the assay is broadly accepted in the field."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "G",
                    "alt": "S",
                   